Antibody Therapy Market Scope And Analysis

  • Report Code : TIPRE00031447
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Antibody Therapy Market Trends and Scope by 2031

Buy Now


Antibody Therapy Market Report Scope

Report Attribute Details
Market size in 2024 US$ 8.4 Billion
Market Size by 2031 US$ 14.20 Billion
Global CAGR (2025 - 2031) 7.80%
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Type
  • Monoclonal Antibody
  • Antibody Drug Conjugates
By End User
  • Hospitals
  • Specialty Centers
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Merck Co Inc
  • Eli Lilly and Company
  • Seagen
  • Novartis AG
  • Takeda Pharmaceuticals
  • Bristol Myers Squibb
  • Johnson Jhonson
  • AstraZeneca
  • Regeneron Pharmaceuticals Inc
  • Industry Developments and Future Opportunities:



    Various initiatives taken by key players operating in the global antibody therapy market are listed below:

    1. In September 2023, The University of Texas MD Anderson Cancer Center and Panacea Venture announced the launch of Manaolana Oncology Inc., a new company created to develop and advance antibody-based therapies against novel cancer antigens.

    2. In March 2022, Sanofi and SeagenInc. Collaborated to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing a specific protein, and Sanofi currently has one ADC in development.

    3. In January 2022, Fate Therapeutics, Inc. received the U.S. Food and Drug Administration (FDA) for the Company’s Investigational New Drug (IND) application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) NK cell product candidate. The Company plans to initiate a clinical investigation of FT536 as a monotherapy and in combination with tumor-targeting monoclonal antibody therapy for the treatment of multiple solid tumor indications.

    4. In July 2021, AstraZeneca entered into a new global development and commercialization agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) and potential new medicine for the treatment of multiple tumor types.

    Competitive Landscape and Key Companies:



    Some of the prominent players operating in the global antibody therapy market include Merck & Co. Inc, Eli Lilly and Company, Seagen, Novartis AG, Takeda Pharmaceuticals, Bristol-Myers Squibb, Johnson & Jhonson, AstraZeneca, Regeneron Pharmaceuticals Inc, Amgen, among others. These companies focus on new product launches and geographical expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. They have a widespread global presence, which allows them to serve a large set of customers and subsequently increases their market share.